Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0
- 28 June 2017
- journal article
- research article
- Published by Springer Nature in Neurocritical Care
- Vol. 27 (3) , 334-340
Abstract
Prothrombin complex concentrates (PCCs) have become the first-line therapy for warfarin reversal in the setting of central nervous system (CNS) hemorrhage. Randomized, controlled studies comparing agents for warfarin reversal excluded patients with international normalized ratio (INR) <2, yet INR values of 1.6–1.9 are also associated with poor outcomes.Keywords
This publication has 35 references indexed in Scilit:
- An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergenciesHaematologica, 2012
- Evidence-Based Management of Anticoagulant TherapyChest, 2012
- Effect of Prothrombin Complex Concentrate on Hematoma Enlargement and Clinical Outcome in Patients with Anticoagulant-Associated Intracerebral HemorrhageCerebrovascular Diseases, 2010
- Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapyTransfusion Medicine, 2010
- Massive, Fatal, Intracardiac Thrombosis Associated With Prothrombin Complex ConcentrateAnnals of Emergency Medicine, 2009
- Hematoma Growth in Oral Anticoagulant Related Intracerebral HemorrhageStroke, 2008
- The Necessity to Assess Anticoagulation Status in Elderly Injured PatientsJournal of Trauma: Injury, Infection & Critical Care, 2008
- Warfarin use leads to larger intracerebral hematomasNeurology, 2008
- Hematoma Growth and Outcome in Treated Neurocritical Care Patients With Intracerebral Hemorrhage Related to Oral Anticoagulant TherapyStroke, 2006
- Safety and Feasibility of Recombinant Factor VIIa for Acute Intracerebral HemorrhageStroke, 2005